MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD – Get Free Report) shares traded down 4.1% during mid-day trading on Monday . The stock traded as low as $1.86 and last traded at $1.86. 39,968 shares traded hands during trading, a decline of 74% from the average session volume of 153,066 shares. The stock had previously closed at $1.94.
MyMD Pharmaceuticals Stock Performance
The company’s 50 day simple moving average is $2.33 and its 200-day simple moving average is $3.78.
MyMD Pharmaceuticals (NASDAQ:MYMD – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($5.14) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On MyMD Pharmaceuticals
MyMD Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.
Further Reading
- Five stocks we like better than MyMD Pharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- The Top 3 Sectors Poised For Growth This Summer
- What Are Dividends? Buy the Best Dividend Stocks
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.